DxDirect is a combination of DxCollect, a novel nucleic acid stabilization buffer, and Chemical Ligation Dependent Probe Amplification (CLPA), a robust detection chemistry. Together, DxDirect provides quantitative, multiplexed genomics at lower cost than any other system for research and pre-clinical studies.


By combining DxCollect, a novel RNA stabilization buffer, and a robust detection chemistry known as Chemical Ligation Dependent Probe Amplification (CLPA), DxDirect provides a unique unified platform for gene expression direct from blood for research and preclinical studies.


DxTerity at AACC 2014

DxTerity Launches DxDirect Reagent Kits for Research

DxTerity Receives CAP Accreditation

DxTerity Announces CLIA Licensure

REDI-DX Radiation Test Performs Well in NATO Study

REDI-Dx Wins 2013 Product of the Year Award

DxTerity Wins SBIR to Develop Radiation Toxicity Test

DxTerity REDI-Dx Functional Exercise with Scottsdale Health and GER911

DxTerity Launches REDI-Dx Reagent Kits for Research

DxTerity Opens New Lab

DxTerity Wins SBIR Grant to Develop FFPE Gene Expression Assays

DxTerity Acquires SourceMDx Assets